newsfilter
← Latest News
ACCESS Newswire·

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SEATTLE, WASHINGTON / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel